Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ayyıldız, Mehmet Orhan"'
Publikováno v:
In Transfusion and Apheresis Science April 2021 60(2)
Autor:
Başaranoğlu, Erol, Aslan, Şükran, Şenyiğit, Abdurrahman, Ayyıldız, Mehmet Orhan, Şen, Hadice Selimoğlu
Publikováno v:
Respiratory Case Reports; Jun2023, Vol. 12 Issue 2, p54-56, 3p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Şit, Dede, Altıntaş, Abdullah, Kadiroğlu, Ali Kemal, Kayabaşı, Hasan, Subaşı, Mehmet, Işıkdoğan, Abdurrahman, Ayyıldız, Mehmet Orhan
Heparin is a drug that is widely used for prophylaxis of thrombosis or treatment in many clinical situations, particularly in surgical clinics and Heparin-induced thrombocytopenia (HIT) is the most important and most frequent druginduced and immun me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3346::407f4bf585fd32bd1b213e2a36eed623
https://app.trdizin.gov.tr/makale/TnpRd09EQXc/
https://app.trdizin.gov.tr/makale/TnpRd09EQXc/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 60(2)
WOS:000636456800011 PMID: 33390328 Introduction: Our purpose was to determine the bleeding risk of obligate and potential carriers, highlight the prophylactic applications before interventions for families and physicians. Method: Forty-six sisters wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::646a76bf74da9c5dbe1ba9b276b4d107
https://pubmed.ncbi.nlm.nih.gov/33390328
https://pubmed.ncbi.nlm.nih.gov/33390328
Autor:
EKMEN, Mehmet Önder, DAL, Sinan, KARAKUŞ, Abdullah, BÜYÜKBAYRAM, Hüseyin, AYYILDIZ, Mehmet Orhan
Publikováno v:
Volume: 16, Issue: 3 556-561
Harran Üniversitesi Tıp Fakültesi Dergisi
Harran Üniversitesi Tıp Fakültesi Dergisi
Amaç: Hodgkin olmayan lenfoma(NHL) alt tiplerinin dağılması tüm dünyada farklılık gösterir. Bu çalışmada,Ocak 2005- Aralık 2014 tarihleri arasında hastanemize başvuran NHL hastalarındacinsiyet, yaş, alt tipler, biyopsi alanları, nod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1ba955710756bf5b39ceab2912f524a5
https://hdl.handle.net/11468/11976
https://hdl.handle.net/11468/11976
Autor:
Özkan, Abdurrahman
Amaç: Dicle Üniversitesi Tıp Fakültesi Hastanesi İç Hastalıkları Hematoloji Polikliniği' ne başvuran polisitemi vera (PV) tanılı hastaların demografik özelliklerini, klinik ve laboratuvar parametreleri ile tedavi yöntemlerini,hastalık
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10208::c8f3d7b28aec3aba3add0aad7594cb8e
https://acikbilim.yok.gov.tr/handle/20.500.12812/111245
https://acikbilim.yok.gov.tr/handle/20.500.12812/111245
Autor:
Sert, Leyla
Amaç: Kronik myeloid lösemi (KML), myeloid seri hücrelerinde aşırı ve kontrolsüz çoğalmayla karakterize olan bir hematopoetik kök hücre hastalığıdır. KML patofizyolojisindeki BCR-ABL proteinini hedef alan TKİ'lerinin geliştirilmesi i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10208::c2d7e29d997890f443c4b7eaed403908
https://acikbilim.yok.gov.tr/handle/20.500.12812/110893
https://acikbilim.yok.gov.tr/handle/20.500.12812/110893
Autor:
Akif Selim Yavuz, Ugur Ozbek, Mustafa Pehlivan, Güray Saydam, Mehmet Sönmez, Rıdvan Ali, Leylagül Kaynar, Zafer Baslar, Demet Aydin, Osman Ilhan, Simten Dagdas, Ibrahim C. Haznedaroglu, Olga Meltem Akay, Birol Guvenc, Orhan Ayyildiz, Ilkiz M. Dag, Bülent Ündar, Gulnur Akin
WOS: 000448137100007
PubMed ID: 29486663
Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods
PubMed ID: 29486663
Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e810501d0345605c9c590da656ad01e2
https://hdl.handle.net/20.500.12605/9241
https://hdl.handle.net/20.500.12605/9241